Targets › SELENOF
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Apr 2027.
May be involved in redox reactions associated with the formation of disulfide bonds (By similarity). May contribute to the quality control of protein folding in the endoplasmic reticulum. (UniProt, O60613)
Open in Phaseline: the race on SELENOF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| First Affiliated Hospital of Chongqing Medical University | selenium yeast supplementation selenium cofactor for selenoprotein synthesis | SELENOP, SELENOK, SELENOW, SELENOF | Phase 2 | Depression - Major Depressive Disorder | Apr 2027 |
Depression - Major Depressive Disorder (1)
small molecule (1)
First Affiliated Hospital of Chongqing Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.